Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
XTLB | US
-0.01
-0.61%
Healthcare
Biotechnology
31/03/2024
24/04/2026
2.43
2.39
2.45
2.39
XTL Biopharmaceuticals Ltd. a biopharmaceutical company engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. Its lead drug candidate is hCDR1 a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research development and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan Israel.
View LessNegative Momentum (Declining Price)
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
40.2%1 month
54.6%3 months
698.3%6 months
508.5%-
-
4.37
-
-
16.54
-
-
-764.00K
13.24M
13.24M
-
-
-76.00
-
-13.07
2.30
1.02
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.28
Range1M
0.66
Range3M
2.40
Rel. volume
0.45
Price X volume
10.12K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Cocrystal Pharma Inc | COCP | Biotechnology | 1.43 | 14.55M | 1.42% | n/a | 10.24% |
| Longeveron Inc. Class A Common Stock | LGVN | Biotechnology | 0.94 | 13.50M | -3.73% | n/a | 11.72% |
| Genenta Science S.p.A | GNTA | Biotechnology | 0.7082 | 12.90M | 0.90% | n/a | 0.00% |
| JSPR | JSPR | Biotechnology | 0.8384 | 12.66M | -7.37% | n/a | 2.31% |
| Marker Therapeutics Inc | MRKR | Biotechnology | 1.4 | 12.49M | -3.45% | n/a | 0.00% |
| CytoMed Therapeutics Limited Ordinary Shares | GDTC | Biotechnology | 0.9507 | 10.97M | -5.87% | n/a | 3.98% |
| HOOKIPA Pharma Inc | HOOK | Biotechnology | 1.1 | 10.88M | 0.00% | n/a | 5.69% |
| InMed Pharmaceuticals Inc | INM | Biotechnology | 0.7714 | 10.29M | 1.22% | n/a | 7.00% |
| Adial Pharmaceuticals Inc | ADIL | Biotechnology | 1.58 | 10.12M | 1.28% | n/a | 0.00% |
| VYNE Therapeutics Inc | VYNE | Biotechnology | 0.6451 | 9.51M | 0.77% | 1.29 | 0.19% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 0.57 | 11.01M | -3.37% | n/a | 58.43% |
| Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.5165 | 7.55M | -0.67% | 0.03 | 16.03% |
| EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.38 | 3.52M | 0.23% | n/a | 17.32% |
| Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.199 | 1.89M | 1.38% | n/a | 19.98% |
| Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 1.27 | 699.77K | -6.62% | n/a | 0.00% |
| Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.0055 | 507.18K | -37.50% | n/a | -37.05% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 16.54 | 0.53 | Expensive |
| Ent. to Revenue | - | 3,967.00 | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 4.37 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 698.25 | 72.80 | Riskier |
| Debt to Equity | - | -1.23 | - |
| Debt to Assets | - | 0.25 | - |
| Market Cap | 13.24M | 3.66B | Emerging |